Continental (OTCMKTS:CTTAY – Get Free Report) and Aspire Biopharma (NASDAQ:ASBP – Get Free Report) are both consumer discretionary companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.
Profitability
This table compares Continental and Aspire Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Continental | -1.36% | -10.86% | -2.63% |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
Valuation and Earnings
This table compares Continental and Aspire Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Continental | $22.26 billion | 0.73 | -$186.68 million | ($0.30) | -26.93 |
| Aspire Biopharma | $10,000.00 | 1,148.00 | -$24.48 million | ($69.62) | -0.12 |
Aspire Biopharma has lower revenue, but higher earnings than Continental. Continental is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
0.0% of Continental shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and price targets for Continental and Aspire Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Continental | 0 | 5 | 4 | 0 | 2.44 |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Volatility and Risk
Continental has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.
Summary
Continental beats Aspire Biopharma on 7 of the 13 factors compared between the two stocks.
About Continental
Continental Aktiengesellschaft, a technology company, offers intelligent solutions for vehicles, machines, traffic, and transportation worldwide. It operates through four sectors: Automotive, Tires, ContiTech, and Contract Manufacturing. The company offers safety, brake, chassis, motion, and motion control systems; solutions for assisted and automated driving; display and operating technologies; and audio and camera solutions for the vehicle interior, as well as intelligent information and communication technology solutions. It also provides tires for cars, trucks, buses, two-wheel, and specialist vehicles, as well as digital tire monitoring and management systems; and engages in retail of tires. In addition, the company develops products and systems made from rubber, plastic, metal and textiles for the energy, agriculture, and construction, as well as interior design, automotive, transportation, and railway engineering sectors; and provides contract manufacturing services. The company was formerly known as Continental-Caoutchouc- und Gutta-Percha Compagnie. Continental Aktiengesellschaft was founded in 1871 and is headquartered in Hanover, Germany.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
Receive News & Ratings for Continental Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Continental and related companies with MarketBeat.com's FREE daily email newsletter.
